首页> 外国专利> Screening assay for identifying agents that modulate pak kinase or cd45 tyrosine phosphatase activity

Screening assay for identifying agents that modulate pak kinase or cd45 tyrosine phosphatase activity

机译:筛选测定以鉴定可调节pak激酶或cd45酪氨酸磷酸酶活性的药物

摘要

Screening assays for identifying an agent that modulates the activity of a phosphate catalyzing enzyme, i.e., a PAK Kinase or a CD45 tyrosine Kinase, comprising the following steps: a) providing a phosphate catalyzing enzyme, b) providing a peptide, c) optionally providing a phosphate containing donor, d) providing a candidate compound, e) contacting the enzyme of step a) with a peptide of step b) and optionally the phosphate containing donor of step c) in the absence of d) and in the presence of d) for a predetermined period of time so that an enzymatic product can be for med, f) transferring at least an aliquot of the enzymatic product formed in step e) to a solid phase which is capable to bind to the peptide in the enzymatic product, g) detecting the enzymatic product bound to the solid phase, h) determining whether there is a difference in the amount of enzymatic product in the absence and in the presence of a candidate compound in step e), and i) choosing an agent that modulated the activity of an enzyme, which method is characterized in that I) the enzyme is a PAK kinase, - the peptide comprises the amico acid sequence S-S-L-R-A-S-T, - the phosphate containing donor of step c) is present in step e), and - the enzymatic product detected in step g) is the amount of phosphoserine and/or phosphothreonine in the bound peptide; OR II) the enzyme is CD45 tyrosine phosphatase, - the peptide comprises the amino acid sequence R-N-Q-E-T-Y-E-T-L-K-H or A-E-N-T-I-T-Y-S-L-L-M-H-P, wherein Y is phosphorylated tyrosine, - the phosphate containing donor of step c) is absent in step e), and - the enzymatic product detected in step g) is the amount of phosphotyrosine in the bound peptide.
机译:用于鉴定调节磷酸催化酶(即PAK激酶或CD45酪氨酸激酶)活性的试剂的筛选试验,包括以下步骤:a)提供磷酸催化酶,b)提供肽,c)任选提供含磷酸盐的供体,d)提供候选化合物,e)在不存在d)和存在d的情况下,使步骤a)的酶与步骤b)的肽和任选地步骤c)的含磷酸盐的供体接触)一段预定的时间,以便可以生产酶促产物; f)将步骤e)中形成的酶促产物的至少等分试样转移至能够与酶促产物中的肽结合的固相, g)检测结合在固相上的酶促产物,h)在步骤e)中确定在不存在和存在候选化合物的情况下酶促产物的量是否存在差异,以及i)选择可调节的试剂Ť酶的活性,该方法的特征在于,I)该酶是PAK激酶,-该肽包含酰胺酸序列SSLRAST,-步骤c)中的含磷酸盐的供体存在于步骤e)中,以及-步骤g)中检测到的酶产物是结合的肽中磷酸丝氨酸和/或磷酸苏氨酸的量;或II)酶是CD45酪氨酸磷酸酶,-该肽包含氨基酸序列RNQETYETLKH或AENTITYSLLMHP,其中Y是磷酸化酪氨酸,-步骤c)中不包含步骤c)的磷酸盐供体,和-检测到的酶产物在步骤g)中,是结合的肽中磷酸酪氨酸的量。

著录项

  • 公开/公告号AU2003293303A8

    专利类型

  • 公开/公告日2004-05-04

    原文格式PDF

  • 申请/专利权人 NOVARTIS AG;

    申请/专利号AU20030293303

  • 发明设计人 FRANZ HAMMERSCHMID;

    申请日2003-09-10

  • 分类号C12Q1/42;C12Q1/48;

  • 国家 AU

  • 入库时间 2022-08-21 23:01:48

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号